Specify Company / Ticker to Get the Summary
180 Life Sciences Corp
ATNF180 Life Sciences Corp., a clinical stage biotechnology company, focuses on developing therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases. The company product development platforms includes fibrosis and anti-tumor necrosis factor (anti-TNF) platform, which has completed phase 2a and phase 2b proof-of-concept clinical trials for early-stage Dupuytren's Contracture; Synthetic Cannabidiol (CBD) Analogs platform, which are synthetic pharmaceutical grade molecules close or distant analogs of non-psychoactive cannabinoids, such as CBD for the treatment of inflammatory diseases and pain; and a7nAChR platform, an immune suppressive, that focuses on alpha 7 nicotinic acetylcholine receptor. The company is headquartered in Palo Alto, California. Address: Building 4, Palo Alto, CA, United States, 94306
Analytics
WallStreet Target Price
80 USDP/E ratio
0.2982Dividend Yield
–Current Year
Last Year
Current Quarter
Last Quarter
Current Year
Last Year
Current Quarter
Last Quarter
Key Figures ATNF
Dividend Analytics ATNF
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History ATNF
Stock Valuation ATNF
Financials ATNF
Results | 2019 | Dynamics |